This is from a Scott Gottlieb editorial in the Wall Street Journal:
Mr. Obama has championed a "comparative effectiveness" agency — styled after England's National Institute for Clinical Evidence (NICE) — that conducts reviews and studies on the clinical and cost effectiveness of drugs to inform central rulings on which patients should be eligible for a new treatment.
NICE's real mission is to protect the British health-care budget. Since 2000 it has denied patients the ability to use the newest cancer drugs — by my count, in 226 different indications where American insurers, and Medicare, currently pay, and where the National Comprehensive Cancer Network says there is "high-level evidence" or "uniform consensus" of clinical benefit. Cancer survival rates in the U.K. are substantially lower than in the U.S. and the gap continues to widen.